Inhaled ciclosporin improves survival in lung transplants
Inhaled ciclosporin improves chronic rejection and survival in lungtransplant patients, a randomised, double-blind trial concludes.
The study, published in The New England Journal ofMedicine, assigned 58 patients to receive either 300mg of aerosolciclosporin or aerosol placebo, three times a week for the first twoyears post-transplant (2006;354:141).
Theauthors found no statistical difference in the rate of acute rejection(the primary end point) between the two groups. However, patients inthe active treatment group had a substantially higher rate of survival(relative risk of death, 0.20; 95 per cent confidence interval,0.06-0.70; P=0.01) and better chronic rejection-free survival (relativerisk of chronic rejection, 0.38; 95 per cent CI, 0.18-0.82; P=0.01)compared with placebo.
The risks of nephrotoxicity and opportunistic infection were similar for both the ciclosporin group and the placebo group.
Citation: The Pharmaceutical Journal URI: 10971372